Jade Biosciences, Inc. (JBIO)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 22,547 | |||
| General and administrative | 5,231 | |||
| Total operating expenses | 27,778 | |||
| Loss from operations | -27,778 | |||
| Interest income | 1,828 | |||
| Change in fair value of convertible notes payable | 6,184 | |||
| Total other expense, net | -4,356 | |||
| Net loss | -32,134 | |||
| Currency translation adjustment | -24 | |||
| Comprehensive loss | -32,158 | |||
| Net loss per share attributable to common stockholders, basic | -0.86 | |||
| Net loss per share attributable to common stockholders, diluted | -0.86 | |||
| Weighted-average common stock outstanding, basic | 28,431,158 | |||
| Weighted-average common stock outstanding, diluted | 28,431,158 | |||